CHEMISTRY, MANUFACTURING & CONTROLS STRATEGY MEETING EAST COAST 2025
ENTER YOUR DETAILS BELOW AND WE'LL SEND YOU MORE INFORMATION
DOWNLOAD THE REPORT
Proventa's latest insights from CMC decision-makers reveal an intensified focus on Process R&D and cGMP as strategic investment anchors. While Al-driven study acceleration promises operational breakthroughs, regulatory timeline pressures remain a critical bottleneck. Driving these investments are expanding product pipelines, the need for seamless clinical and regulatory integration, and the increasing complexity of program development. Staying ahead requires recalibrating CMC strategies to meet evolving standards of speed, quality, and regulatory precision.
May 7th
Le Meridien Boston, Cambridge
